- Home
- News and Resources
- Resources
- The Clock is Ticking: How to Ensure CTIS Readiness Before 2025
The Clock is Ticking: How to Ensure CTIS Readiness Before 2025
The Clinical Trials Information System (CTIS) is reshaping the way clinical trials are conducted and managed in the European Union. With the January 31, 2025 deadline fast approaching, all ongoing clinical trials must be transitioned to CTIS to comply with the EU Clinical Trials Regulation (CTR). This shift promises increased efficiency, harmonization, and transparency—but also brings new challenges for sponsors, CROs, and researchers.
What is CTIS and Why Does It Matter?
The Clinical Trials Regulation (CTR), which came into effect on January 31, 2022, aims to create a more efficient and transparent framework for clinical research in the EU. At the heart of this regulation is CTIS, a centralized platform that will become the mandatory system for all clinical trial applications and management activities across the EU.
- Single-entry point for trial applications across all participating EU countries.
- Harmonization of processes between national competent authorities and ethics committees.
- Public access to trial protocols and results, ensuring greater transparency.
- Simplified reporting and communication requirements between sponsors and regulators.
The transition from the old Clinical Trials Directive (2001/20/EC) to the new CTIS framework requires careful planning and compliance alignment. Failure to meet the 2025 deadline could result in regulatory delays, disruption to ongoing trials, or ineligibility for new submissions.
Key Changes You Need to Know
1. Single Application for Multiple Countries
- Sponsors will submit one application via CTIS for all participating EU countries, eliminating the need for country-specific submissions.
- Sponsors will submit one application to Competent Authorities and Ethic Committees, eliminating the need for separate applications and submissions.
2. Increased Transparency Requirements
- Trial documents—including study protocols, lay summaries, and results—must be uploaded to CTIS and made accessible to the public.
3. Collaborative Assessments Across Countries
- National competent authorities and ethics committees will collaborate on trial assessments, requiring more coordination and alignment from sponsors.
4. New Deadlines for Responses and Reporting
- CTIS introduces fixed timelines for regulatory feedback, which means sponsors must respond promptly to avoid delays.
5. Mandatory Transition of Ongoing Trials by January 31, 2025
- Any trial approved under the previous directive must transition into CTIS or risk being unable to continue operating legally in the EU.
How Amarex Can Support Your Transition to CTIS
Amarex, as part of NSF, combines clinical trial expertise with regulatory knowledge to provide end-to-end solutions for sponsors navigating the complexities of CTIS. Our experience in clinical operations, project management, and regulatory compliance ensures a smooth transition—whether you are just getting started or need last-minute support.
Here’s how we can help:
1. CTIS Readiness Assessments
- We’ll audit your current trials and processes to identify gaps in compliance with the new CTIS framework.
2. Regulatory Strategy and Submission Planning
- Our team will develop a CTIS-specific submission strategy tailored to your trial portfolio, ensuring compliance and avoiding delays.
3. Training for Your Teams
- We offer CTIS-specific training to ensure your teams are fully prepared to manage the new platform and meet the required timelines.
4. Data Preparation and Migration Support
- Amarex will assist with document preparation, data migration, and public disclosure requirements to meet CTIS transparency obligations.
5. Ongoing Compliance Monitoring and Reporting
- We’ll provide compliance tracking and support for reporting requirements, ensuring smooth collaboration with regulators and ethics committees.
Urgent Steps You Need to Take Today
If you haven’t yet started preparing for CTIS, the time to act is now. With January 31, 2025, fast approaching, sponsors need to take immediate action to avoid disruptions. Here’s what you should do right away:
1. Assess Your Portfolio
- Identify any ongoing trials approved under the old directive and prioritize their transition into CTIS.
2. Establish a CTIS Implementation Team
- Assign a cross-functional team responsible for managing the transition and ensuring all regulatory requirements are met.
3. Develop a Timeline for Compliance
- Map out milestones and deadlines for submission, migration, and training to stay on track with the regulatory schedule.
4. Engage with a Regulatory Partner
- Collaborate with experts like Amarex to streamline your transition and avoid costly errors or delays.
The Cost of Inaction
Delaying your preparation for CTIS can lead to serious consequences:
- Regulatory delays that disrupt trial operations and timelines.
- Inability to submit new trials or continue ongoing ones after January 31, 2025.
- Increased costs due to last-minute scrambling and errors.
Don't wait until it's too late. Contact us for a free consultation call today and let us help you take the next step in your CTIS journey—so you can focus on developing life-changing therapies while we handle the regulatory complexities.